久久评测

说话挑选:简体 / 繁體 / English

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

山东罗欣药业团体股分无限公司投标通知布告

企业资讯

罗欣药业与印度阿拉宾度制药告竣计谋协作,在华共建合伙企业引进高品质廉价格药品

颁布发表时候:2018年12月25日 阅读次数:
分享:

2018年12月23日,上海 -- 山东罗欣药业股分无限公司(以下简称“罗欣药业”)颁布发表公司与印度阿拉宾度制药无限公司(Aurobindo Pharma,以下简称“阿拉宾度制药”)签定计谋协作和谈,两边将配合在中国设立合伙公司,结合投资研发和出产系统以引进呼吸范畴产物。阿拉宾度制药将经由过程合伙公司把更多具备手艺壁垒的呼吸范畴产物及手艺转移到中国,并且完本钱地化出产;合伙公司将具备浩繁已在美国和欧洲获得上市批件的产物,将来将延续给中国、美国及欧洲市场供货,为三地的患者带来更多更好的用药挑选。

Shanghai, China - Dec, 23 2018 -- Shandong Luoxin Pharmaceutical Group (hereinafter referred to as "Luoxin Pharmaceutical") today announced the company has reached an agreement with Aurobindo Pharma Co., Ltd. (hereinafter referred to as "Aurobindo Pharma") to establish a joint venture company in China and invest in both R&D and manufacturing systems on respiratory products. Aurobindo Pharma will transfer respiratory products and technical know-hows with technologic barriers to China for local manufacturing; the joint venture company will possess numerous products approved by US FDA and EMA, and manufacture respiratory products to supply China, US and EU markets to provide more and better options for patients in those regions. 

阿拉宾度制药是环球前五大仿造药制药公司,1992年在印度上市。公司具备很是健旺的产物线,首要专一于呼吸系统、中枢神经系统、血汗管系统、消化系统、抗传染、抗逆转录病毒(HIV)、糖尿病和抗过敏等医治范畴。公司产物具备优良的品质和有协作力的本钱,发卖涵盖美国、欧洲、新兴市场等150多个国度,具备很强的产物供给才能。经由过程本身的研发才能,阿拉宾度制药敏捷在环球规模内请求专利、DMFs、ANDAs和仿造药手艺材料,今朝是印度DMFs备案和ANDAs报告最多的仿造药企业。阿拉宾度制药大都工场都经由过程了美国FDA和欧盟COS 认证,使其产物不时向着高手艺、高附加值和高端市场迈进。本年9月,阿拉宾度收买了仿造药巨子山德士在美国的营业,使其成为美国市场第二大仿造药企业。

Aurobindo Pharma, a publicly listed company in India since 1992, is a top 5 generic pharmaceutical company globally. The company boasts a strong R&D pipeline focused on respiratory, central nerve system, cardiovascular, gastrointestinal track, anti-infectious, anti-HIV, diabetes, and other therapeutic areas. The products are of high quality, affordability and supply-chain sustainability, and have been sold in more than 150 countries across US, EU and emerging markets. The company has the most DMF and ANDA applications among all India generic companies, and many of its manufacturing sites are FDA and COS certified. The company acquired the commercial operations in the US from Sandoz in September this year, making it the second largest generic company in US.  

中国今朝存在很是大的未知足的临床需要。比来国度医疗保证局主导的“4+7”试点结合推销政策启动后,可以或许为泛博患者供给更高品质、更廉价格的产物显得尤其主要。近期国度对于优化药品注册审评审批和接管药品境外临床尝试数据的政策,给国际优良药品进入中国缔造了加倍方便的前提。在国际市场规模内,印度制药企业具备很是强的品质和本钱协作上风,罗欣药业与阿拉宾度制药的牵手因此具备主要的计谋意思。罗欣药业将持续借助多年的对外协作经历,努力于把更多优异的国际产物和手艺落地,为中国患者带来更多更好的产物挑选,并为下降国度医疗用度收入进献本身的气力。

China still faces enormous unmet medical needs. After the recent implementation of ‘4+7 Quantity Procurement’ policy enacted by the central government, it is of paramount importance to provide patients with high quality and affordable medicines.  The recent new regulations on expediting regulatory processes and acceptance of overseas clinical study data have a positive impact on bringing high quality pharmaceutical products from overseas into China market. Under these circumstances, the collaboration between Luoxin and Aurobindo is of great strategic importance given the competiveness of Indian pharmaceutical companies in terms of quality and cost. Luoxin Pharma will continue to utilize its rich experience in external collaboration and bring more high quality products into China, thus benefiting the patients and helping alleviate the medical expense burden.  

罗欣药业履行董事长刘振腾表现:“罗欣药业很是正视与以阿拉宾度制药为代表的国际仿造药巨子公司的协作,咱们一方面等候与阿拉宾度进一步切磋更多产物及贸易形式的协作,同时也但愿与更多优异的国际外企业协作,操纵罗欣药业多年成立起来的全财产链上风,经由过程资本整合完成多方双赢的形式,为协作火伴赋能,终究让中国的老百姓、中国医药市场和国度受害。”

Mr. Ryan Liu, the Executive Chairman of Luoxin Pharma said, “Luoxin highly values the collaboration with Aurobindo. While we expect to hold further discussions with Aurobindo on products and business models, we look forward to collaborating with more outstanding pharmaceutical companies, domestic and abroad. Our ultimate strategic goal is to achieve win-win situations and energize our partners via Luoxin’s advantages in the whole healthcare value chain established over the years, eventually benefiting the Chinese patients, the Chinese healthcare industry, and the country.”